Specific Polo-Like Kinase 1 Expression in Nodular Lymphocyte-Predominant Hodgkin Lymphoma Suggests an Intact Immune...

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an indolent B-cell lymphoma characterized by specific tumor cells within a lymphocytic microenvironment.
• Aggressive lymphomas often show nuclear expression of polo-like kinase 1 (PLK1), a protein linked to MYC stabilization and poorer outcomes.

Purpose of the Study:

• To investigate the expression and functional role of PLK1 in NLPHL.
• To explore the association between PLK1 expression, tumor microenvironment, and clinical parameters in NLPHL.

Main Methods:

• Immunohistochemistry was used to assess PLK1 expression in NLPHL and classic Hodgkin lymphoma patient samples.
• Loss-of-function experiments were performed on NLPHL cell lines to determine PLK1's effect on proliferation and MYC stability.
• Multiplex immunofluorescence and AI algorithms analyzed the tumor microenvironment in relation to PLK1 expression.

Main Results:

• PLK1 was expressed in 100% of NLPHL cases but <5% of classic Hodgkin lymphoma cases.
• PLK1 expression promoted NLPHL cell proliferation and increased MYC stability.
• High PLK1 expression correlated with advanced-stage disease and an increased presence of cytotoxic and T-regulatory cells in the tumor microenvironment.

Conclusions:

• PLK1 signaling drives NLPHL proliferation and represents a potential therapeutic target.
• PLK1 inhibitors could be a viable treatment option for NLPHL.
• Immune surveillance may play a role in limiting PLK1-driven tumor growth in NLPHL.